### **Overview** Solara Active Pharma Sciences Ltd is a globally recognized **pure-play manufacturer of Active Pharmaceutical Ingredients (APIs)**, offering end-to-end solutions in **API development and Contract Development and Manufacturing (CDMO/CRAMS)** services. With over **three decades of industry experience**, the company serves more than **70 countries** across regulated markets including North America, Europe, Japan, South Korea, and the Middle East & North Africa (MENA). It operates **six state-of-the-art, multi-product manufacturing facilities and one dedicated R&D center**, supported by a workforce of over **2,100 employees**. --- ### **Key Business Highlights (as of Nov 2025)** #### ✅ **Global Presence & Regulatory Excellence** - Manufacturing facilities are approved by **USFDA, EDQM, PMDA (Japan), MFDS (South Korea), WHO, and EU GMP**, reflecting strict adherence to global quality standards. - Recent inspections at its **Vizag and Ambernath** facilities resulted in **zero USFDA Form 483 observations**, underscoring robust regulatory compliance. - WHO approvals were secured in May 2025 for facilities in **Mangalore, Ambernath, and Pondicherry**. #### ✅ **Manufacturing & Capacity** - Total reactor capacity: **2,673 kiloliters** across six facilities. - Facilities support both **large-volume and specialty small-batch production**, ensuring flexibility. - **Mirrored production capabilities** across sites enhance supply chain resilience and reduce dependency on single locations. - Advanced chemical processes mastered: **hydrogenation, high-vacuum distillation, Grignard reactions, halogenation, lyophilisation, polymer chemistry, photochemistry, flow chemistry, and chiral synthesis**. #### ✅ **Product Portfolio & Therapeutic Focus** - Offers **60+ commercial APIs**, with **10 new molecules under active development.** - Therapeutic areas include: - Pain management - Anti-infectives & anti-malarials - Anti-convulsants & anesthetics - Anti-psychotics - Anthelmintics - Antihyperkalemia (e.g., Patiromer, Sevelamer derivatives) - Strong expertise in **complex, high-value APIs** such as: - **Polymer-based therapeutics** (Sevelamer Carbonate, Colesevelam, Patiromer) - **Iron-based APIs** - **Injectables and High Potent APIs (HPAPIs)** --- ### **Strategic Direction & Financial Performance** #### 📈 **Refocus on Core API Business & Profitability** - In FY25, **76% of revenue originated from regulated markets**—stable, long-term, and less price-sensitive. - Reduced **net debt by INR 223.4 crores (~22%)** in FY25. - Implemented **cost optimization**, improved **capacity utilization (65% current core utilization)**, and **inventory rationalization**, leading to better margins. - Shifted strategy from **volume to value**: - Reduced ibuprofen-related contribution from 50% to ~30% of sales. - Plain ibuprofen now accounts for **~21% of sales**, with derivatives adding **~9%**. - Top 5 molecules contribute **55–60% of total revenue**, top 10 account for **84%**—highlighting concentration risk now being actively mitigated. #### 💡 **Demerger of CRAMS & Polymers Business** - Strategic decision to **demerge CRAMS and Polymers segments** into a separately listed entity: **Synthix Global Pharma Solutions Limited**, a wholly owned subsidiary. - Objectives: - Sharpen focus on high-margin **Catalog API** operations. - Unlock shareholder value by creating two distinct, scalable businesses. - De-risk core operations and improve financial transparency. - **Vizag facility**, one of India’s largest API plants, will be **fully dedicated to CRAMS platform**, retrofitting into a multipurpose site for **HPAPIs and polymer-based APIs**. - **INR 200 crores of debt** will be transferred to the new entity; post-restructuring, **Catalog API business to have net debt of ~INR 3,000 crores and debt/EBITDA of ~1.5x**. - Once separation completes (expected **12–15 months**), the **retained Solara entity** will target a **debt/EBITDA ratio close to 1x**, enabling stronger reinvestment capacity. --- ### **R&D & Technical Capabilities** #### 🔬 **State-of-the-Art R&D Infrastructure** - Over **140 scientists** (as of Aug 2024) engaged in innovation and development. - Facilities include: - **Seven synthesis labs** - **60 fume hoods** - Dedicated **HPAPI, flow chemistry, photochemistry, and process safety labs** - Advanced instrumentation: **solid-state NMR, LCHRMS, pXRD, zeta sizing, gel permeation chromatography** - Offers **end-to-end CRAMS services** for novel chemical entities: - Hit-to-lead & lead optimization - Preclinical development - cGMP clinical manufacturing (Phases I–III) - Commercial validation and lifecycle management - Maintains **flexible IP policy** with customer ownership and sublicensing options to encourage collaboration. --- ### **Leadership & Strategic Vision** #### 🧭 **Experienced Leadership Team** - **Mr. Vishal Mathur**, Chief Business Officer (joined Feb 2025), brings 25+ years of global API experience: - Formerly led $160M API business at Cohance Lifesciences. - **Doubled API revenues** at Emcure; built “API Plus” vertical with **>70% gross margins**. - Spearheaded rapid **Favipiravir commercialization** during the pandemic at Glenmark. - Leadership now focused on **internal repositioning**, not external acquisitions, to strengthen core operations first. --- ### **Subsidiary Structure (as of Aug 2024)** - **100% owned**: - Sequent Penems Private Limited (India) - Shasun USA Inc (USA) - Solara Active Pharma Sciences LTDA (Brazil) - **49% stake**: Chemsynth Laboratories Private Limited (India) ---